Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 18 for:    abbott ensite
Previous Study | Return to List | Next Study

EnSite Precision Observational Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03260244
Recruitment Status : Completed
First Posted : August 24, 2017
Last Update Posted : April 7, 2020
Sponsor:
Information provided by (Responsible Party):
Abbott Medical Devices

Tracking Information
First Submitted Date July 5, 2017
First Posted Date August 24, 2017
Last Update Posted Date April 7, 2020
Actual Study Start Date September 12, 2017
Actual Primary Completion Date January 17, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: August 21, 2017)
  • Summary of subjects that used EnSite™ AutoMap and AutoMark module [ Time Frame: during procedure ]
    Overall usage of EnSite™ AutoMap Module. This will be summarized by the number and proportion of subjects with a procedure that use EnSite™ AutoMap. Overall usage of AutoMark module. This will be summarized by the number and proportion of subjects with a procedure that use AutoMark.
  • Summary of EnSite™ Automap and AutoMark Module software settings used per arrhythmia [ Time Frame: during procedure ]
    Among the subjects with EnSite™ AutoMap and AutoMark module features used during the procedure, the settings of EnSite™ AutoMap and AutoMark features will be summarized descriptively by each arrhythmia, as number and proportion or mean and standard deviation as appropriate.
  • Mapping time associated with (re-)mapping one or multiple arrhythmias per catheter type used in a single subject [ Time Frame: during procedure ]
    Mapping time will be summarized (e.g. as mean, median, standard deviation, minimum and maximum) across arrhythmia types and for each type of arrhythmia per catheter, as appropriate for the different map types.
  • Used Points per Minute per catheter type stratified by arrhythmia type and mapping type [ Time Frame: during procedure ]
    Mapping points per minute used will be summarized (e.g. as mean, median, standard deviation, minimum and/or maximum) across arrhythmia types and for each type of arrhythmia per catheter as appropriate, for the different map types
  • Rate of acute success based on pre-defined procedural endpoints [ Time Frame: during procedure ]
    The number and proportion of subjects with acute success will be summarized.
  • Freedom from arrhythmia recurrence [ Time Frame: From date of procedure until the date of first documented arrhythmia recurrence or date of study completion or withdrawal for any cause, whichever came first, assessed up to 12 months ]
    This analysis will be performed using the Kaplan-Meier (KM) analyses. The start date is the date of the index procedure. For subjects who do not experience an event, their follow up duration will be defined from the start date to the date of death, withdrawal, or last follow-up, whichever occurred later.
  • Number of repeat ablations up to 12 months. [ Time Frame: 1 year ]
    This will be summarized as the total count of repeat ablations up to 12 months and the total number of subjects who experience at least one repeat ablation up to 12 months among all subjects in analysis population.
  • Summary of NavX Patch placement locations used [ Time Frame: during procedure ]
    The number and proportion of subjects with NavX patches (Surface Electrode Patches) placed by location
  • Number of gaps in lesions identified during the procedure that require touch-up ablation [ Time Frame: during procedure ]
    The number and proportion of subjects with gaps in lesions identified will be summarized and reported. The summary of number of gaps identified will be reported. The number and proportion of subjects where the AutoMark Module assisted in identifying these gaps will be summarized and reported.
  • Changes in EQ-5D quality of life score at 6 and 12 months [ Time Frame: 1 year ]
    Changes in EQ-5D at 6 months from baseline, and changes in EQ-5D score at 12 months from baseline will be summarized.
  • Number of unscheduled visits and hospitalizations due to arrhythmia [ Time Frame: 1 year ]
    The number of unscheduled visits due to arrhythmia, or hospitalizations due to arrhythmia will be summarized per subject and presented as the number of subjects
  • Overall procedure time [ Time Frame: during procedure ]
    Overall procedure time for the index procedure will be summarized e.g. as mean, standard deviation, minimum and/or maximum. Procedure time will be derived as (Procedure stop time (Last catheter out) - Procedure start time (first catheter in)).
  • Overall system stability [ Time Frame: during procedure ]
    Proportion of subjects with the system stable throughout the procedure. System stability will be based on the opinion of the investigator.
Original Primary Outcome Measures Same as current
Change History
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title EnSite Precision Observational Study
Official Title A Clinical Evaluation Using EnSite Precision Cardiac Mapping System (Software Version 2.0.1 or Higher) in a Real-World Environment
Brief Summary

This document is a clinical investigation plan (CIP) for the EnSite Precision Observational Study.

This clinical study is intended to quantify and characterize the usage of the EnSite Precision™ Cardiac Mapping System (Software version 2.0.1 or higher) in a real-world environment. This study will be conducted in patients who are indicated for a cardiac electrophysiological (EP) mapping and radio frequency ablation procedure using a three-dimensional system.

Detailed Description

The EnSite Precision™ Cardiac Mapping System is a newly developed system that introduces features such as Delayed Enhancement Magnetic Resonance Imaging (DE-MRI) image integration, lesion marking automaticity, automatic mapping, and workflow flexibility to aid in the success of complex ablation procedures. Utilization of this system in the treatment of complex ablation procedures and its impact on patient outcomes is not well characterized. This clinical study is designed to collect a broad range of usage scenarios, therefore this clinical study has limited patient selection criteria and data collection is focused on EnSite Precision™ Cardiac Mapping System usage and patient outcomes.

The data collected from the procedure (performed per Instructions For Use (IFU) and per standard practice of the physician) as well as the 12 month follow up period enables the Sponsor to review the system's standard practice usage. This information will be added to the current knowledge and understanding of treatment options for patients with arrhythmias, which can assist the Sponsor to provide future recommendations for best practices to improve patient outcomes.

Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population The intended population for this clinical study is patients over the age of 18 years who are eligible for a cardiac EP mapping and RF ablation procedure using the EnSite Precision™ Cardiac Mapping System.
Condition Cardiac Arrhythmia
Intervention Procedure: cardiac mapping and radiofrequency ablation procedure

It is a minimally invasive procedure which can be performed using either general or conscious sedation. During catheter ablation, catheters (narrow, flexible tubes) are inserted into a blood vessel, often through a site in the groin (upper thigh) or neck, and guided through the vein until they reach the heart. Small electrodes on the tip of the catheters stimulate and record the heart's activity. This test, called an electrophysiology study (EPS), allows the doctor to pinpoint the exact location of the short circuit. Another word for pinpointing the exact location of the short circuit is 'mapping', for which precision is a key requirement to maximize a successful outcome.

Once the location is confirmed, the short circuit is either destroyed (to reopen the electrical pathway) or blocked (to prevent it from sending faulty signals to the rest of the heart).

Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: April 6, 2020)
1065
Original Estimated Enrollment
 (submitted: August 21, 2017)
1053
Actual Study Completion Date March 31, 2020
Actual Primary Completion Date January 17, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Indicated for a cardiac EP mapping and RF ablation procedure using a 3D mapping system per IFU
  • Over 18 years of age
  • Able to provide informed consent for study participation and willing and able to comply with the protocol described evaluations and follow up schedule

Exclusion Criteria:

  • Patients who are only presenting with:

    • Atrioventricular Nodal Reentrant Tachycardia (AVNRT)
    • Atrioventricular Reentrant Tachycardia (AVRT)
  • Planned cryoablation procedure
  • Implanted with a neurostimulator
  • Contraindication to anticoagulation
  • Known presence of cardiac thrombus
  • Recent (<3 months) myocardial infarction or unstable angina or coronary artery by-pass
  • Currently enrolled in a clinical study/investigation evaluating another device or drug that would confound the results of this study
  • Pregnant or nursing
  • Individuals whose willingness to volunteer in a study, in the judgement of investigator or public authorities, could be unduly influenced by lack of or loss of the autonomy due to immaturity, or mental disability, or adverse personal circumstances, or hierarchical influence
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT03260244
Other Study ID Numbers SJM-CIP-10159
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
IPD Sharing Statement
Plan to Share IPD: No
Responsible Party Abbott Medical Devices
Study Sponsor Abbott Medical Devices
Collaborators Not Provided
Investigators
Study Director: Kristin Ruffner, PhD Abbott
PRS Account Abbott Medical Devices
Verification Date April 2020